In this blog, Michael Todd volunteers his time to post content from public sources on how start-ups, venture partnerships, and large corporations involved in 3d printing secure and manage their funding and growth efforts. No original commentary is provided, and Michael is not in possession of material non-public insider information, nor are his writings intended as investment advice.
A German company created an IndieGoGo campaign to create filaments that could be used to create custom sized drug prescriptions based on patient size, weight, age, etc.
Vancouver-based Aspect Biosystems , founded in 2013, announced the closing of an oversubscribed seed round funded by the local Vancouver Angel community. Like Organovo, Aspect hopes to print human organs.
3D bioprinting startup BioBots has just surpassed the $300k mark on their FundersClub campaign.
Medical technology company ConforMIS, Inc. (NASDAQ: CFMS) has developed a knee replacement system that promises to drastically reduce both the length of the average knee replacement surgery as well as the patient recovery time.
Likely stemmed by the recent drop in their share price, Organovo put forth a detailed explanation for their secondary offering of $40 million in shares, explaining why they’ve taken this route, and what it will mean for their 3D printed human tissue moving forward.
Organovo Holdings, Inc. (NYSE MKT: ONVO) announced the sale of 9,425,000 shares of its common stock in an underwritten public offering at a price to the public of $4.25 per share.
The “Open Source Nano Replicator Initiative” launched a $500 million dollar Indiegogo campaign to create the world’s first nano-replicator, basically a Star Trek-like molecular-level replicator.
Cyfuse Biomedical and Cyberdyne signed a $12 million deal to develop and market the Regenova 3D tissue printing system.